심장 바이오마커 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of cardiac biomarkers Market

The global cardiac biomarkers market plays a critical role in the early diagnosis and management of cardiovascular diseases (CVDs). Cardiac biomarkers are endogenous substances such as enzymes, hormones, and proteins that are released into the bloodstream during abnormal cardiac events. These biomarkers assist healthcare professionals in diagnosing life-threatening conditions such as myocardial infarction, acute coronary syndrome (ACS), and congestive heart failure.

According to Fortune Business Insights, the global cardiac biomarkers market was valued at USD 20.9 billion in 2025. The market is projected to grow to USD 23.45 billion in 2026 and further reach USD 60.29 billion by 2034, registering a compound annual growth rate (CAGR) of 12.53% during 2026-2034. The strong growth outlook is supported by increasing cardiovascular disease prevalence, technological advancements, and rising adoption of rapid diagnostic tests.

Market Size and Key Metrics

• 2025 Market Size: USD 20.9 billion
• 2026 Market Size: USD 23.45 billion
• 2034 Market Size: USD 60.29 billion
• CAGR (2026-2034): 12.53%
• Dominant Region (2025): North America (38.94% market share)

North America dominated the market in 2025 due to advanced healthcare infrastructure, a high incidence of cardiovascular diseases, and early adoption of innovative biomarker testing technologies.

Market Trends

One of the most prominent trends shaping the cardiac biomarkers market is the increasing adoption of point-of-care (POC) biomarker testing. POC tests significantly reduce diagnosis time compared to conventional laboratory-based testing. For instance, Roche's Elecsys Troponin T Gen 5 Stat test provides results in approximately nine minutes, improving emergency care efficiency. This trend is gaining traction in both developed and emerging economies.

Market Drivers

The rising prevalence of cardiovascular diseases is the primary driver of market growth. Lifestyle factors such as smoking, obesity, diabetes, and physical inactivity are contributing to the increasing burden of heart diseases globally. Additionally, the COVID-19 pandemic highlighted the vulnerability of patients with pre-existing cardiovascular conditions. Studies showed higher risks of myocardial injury, myocarditis, and heart failure among COVID-19 patients, which significantly increased demand for cardiac biomarker testing during the pandemic period.

Another key driver is the introduction of novel and high-sensitivity biomarker tests. Regulatory approvals for advanced troponin assays from companies such as Siemens and Abbott have improved early and accurate detection of cardiac events, further boosting market adoption.

Market Restraints

Despite strong growth prospects, the market faces challenges such as limited availability of point-of-care testing kits and delayed test results from laboratory-based methods. Some biomarkers, including CK-MB, require several hours post-symptom onset to be detectable, which can delay diagnosis and treatment, particularly in emergency settings.

Segmentation Analysis

By Indication, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and others. The acute coronary syndrome segment dominated with a 55.74% share in 2026, driven by the rising incidence of ACS globally.

By Biomarker Type, troponin held the largest share at 50.26% in 2026, owing to its high specificity and widespread use in diagnosing myocardial infarction and ACS. Other segments include creatine kinase, BNP, myoglobin, and others.

By End User, hospitals dominated the market with a 52.32% share in 2026, supported by increasing hospital admissions, expanding infrastructure in developing countries, and favorable reimbursement policies.

Regional Analysis

• North America: Market size reached USD 8.14 billion in 2025 and remains the leading region.
• Europe: Strong growth driven by increasing myocardial infarction and ACS cases.
• Asia Pacific: Expected to grow at a significant CAGR due to expanding healthcare infrastructure and rising adoption in China, India, and Japan.
• Latin America & Middle East & Africa: Moderate growth due to limited awareness and slower technology adoption.

Key Industry Players

Major players operating in the global cardiac biomarkers market include F. Hoffmann-La Roche AG, Abbott, Siemens AG, Beckman Coulter, Bio-Rad Laboratories, Thermo Fisher Scientific, and bioMerieux SA. These companies focus on innovation, product launches, and regulatory approvals to strengthen their market positions.

Conclusion

In conclusion, the global cardiac biomarkers market is poised for robust growth from 2025 to 2034, driven by the increasing prevalence of cardiovascular diseases, technological advancements, and rising demand for rapid diagnostic solutions. With the market expected to grow from USD 20.9 billion in 2025 to USD 60.29 billion by 2034, cardiac biomarkers will remain a cornerstone of modern cardiovascular diagnostics. Continued innovation, improved accessibility of point-of-care testing, and expanding healthcare infrastructure-particularly in emerging economies-will play a crucial role in shaping the future of this market.

Unit Value (USD billion)

Segmentation By Indication

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Others

By Biomarker

• Troponin
• Creatine Kinase-MB (CK-MB)
• B-type Natriuretic Peptide (BNP)
• Myoglobin
• Others

By End User

• Hospitals
• Specialty Clinics

By Geography

• North America (the U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• The Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Cardiovascular Disorders, By Key Regions/ Key Countries, 2025
• 4.2. Overview of Impact of COVID-19 on the In-vitro Diagnostics Market
• 4.3. New Product Launches, By Key Market Players
• 4.4. Key Industry Developments such as Mergers and Acquisitions
• 4.5. Key Steps Taken by Companies, Government, etc. to Navigate the Impact of Covid-19
• 4.6. Overview: Impact of Covid-19 on Cardiac Tests

5. Global Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Myocardial Infarction
  • 5.2.2. Congestive Heart Failure
  • 5.2.3. Acute Coronary Syndrome
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Biomarkers
  • 5.3.1. Troponin
  • 5.3.2. Creatine kinase-MB (CK-MB)
  • 5.3.3. B-type natriuretic peptide (BNP)
  • 5.3.4. Myoglobin
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals
  • 5.4.2. Speciality Clinics
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Myocardial Infarction
  • 6.2.2. Congestive Heart Failure
  • 6.2.3. Acute Coronary Syndrome
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Biomarkers
  • 6.3.1. Troponin
  • 6.3.2. Creatine kinase-MB (CK-MB)
  • 6.3.3. B-type natriuretic peptide (BNP)
  • 6.3.4. Myoglobin
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals
  • 6.4.2. Speciality Clinics
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Myocardial Infarction
  • 7.2.2. Congestive Heart Failure
  • 7.2.3. Acute Coronary Syndrome
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Biomarkers
  • 7.3.1. Troponin
  • 7.3.2. Creatine kinase-MB (CK-MB)
  • 7.3.3. B-type natriuretic peptide (BNP)
  • 7.3.4. Myoglobin
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals
  • 7.4.2. Speciality Clinics
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Myocardial Infarction
  • 8.2.2. Congestive Heart Failure
  • 8.2.3. Acute Coronary Syndrome
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Biomarkers
  • 8.3.1. Troponin
  • 8.3.2. Creatine kinase-MB (CK-MB)
  • 8.3.3. B-type natriuretic peptide (BNP)
  • 8.3.4. Myoglobin
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals
  • 8.4.2. Speciality Clinics
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Myocardial Infarction
  • 9.2.2. Congestive Heart Failure
  • 9.2.3. Acute Coronary Syndrome
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Biomarkers
  • 9.3.1. Troponin
  • 9.3.2. Creatine kinase-MB (CK-MB)
  • 9.3.3. B-type natriuretic peptide (BNP)
  • 9.3.4. Myoglobin
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals
  • 9.4.2. Speciality Clinics
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Indication
  • 10.2.1. Myocardial Infarction
  • 10.2.2. Congestive Heart Failure
  • 10.2.3. Acute Coronary Syndrome
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Biomarkers
  • 10.3.1. Troponin
  • 10.3.2. Creatine kinase-MB (CK-MB)
  • 10.3.3. B-type natriuretic peptide (BNP)
  • 10.3.4. Myoglobin
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospitals
  • 10.4.2. Speciality Clinics
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2021)
• 11.3. Company Profiles (Overview, Products, SWOT, Recent Developments, Strategies, and Financials (based on availability))
  • 11.3.1. F. Hoffmann-La Roche AG
    • 11.3.1.1. Overview,
    • 11.3.1.2. Products,
    • 11.3.1.3. SWOT,
    • 11.3.1.4. Recent Developments,
    • 11.3.1.5. Strategies,
    • 11.3.1.6. Financials (based on availability)
  • 11.3.2. Abbott
    • 11.3.2.1. Overview,
    • 11.3.2.2. Products,
    • 11.3.2.3. SWOT,
    • 11.3.2.4. Recent Developments,
    • 11.3.2.5. Strategies,
    • 11.3.2.6. Financials (based on availability)
  • 11.3.3. Siemens AG
    • 11.3.3.1. Overview,
    • 11.3.3.2. Products,
    • 11.3.3.3. SWOT,
    • 11.3.3.4. Recent Developments,
    • 11.3.3.5. Strategies,
    • 11.3.3.6. Financials (based on availability)
  • 11.3.4. Creative Diagnostics
    • 11.3.4.1. Overview,
    • 11.3.4.2. Products,
    • 11.3.4.3. SWOT,
    • 11.3.4.4. Recent Developments,
    • 11.3.4.5. Strategies,
    • 11.3.4.6. Financials (based on availability)
  • 11.3.5. Beckman Coulter, Inc.
    • 11.3.5.1. Overview,
    • 11.3.5.2. Products,
    • 11.3.5.3. SWOT,
    • 11.3.5.4. Recent Developments,
    • 11.3.5.5. Strategies,
    • 11.3.5.6. Financials (based on availability)
  • 11.3.6. Bio-Rad Laboratories, Inc.
    • 11.3.6.1. Overview,
    • 11.3.6.2. Products,
    • 11.3.6.3. SWOT,
    • 11.3.6.4. Recent Developments,
    • 11.3.6.5. Strategies,
    • 11.3.6.6. Financials (based on availability)
  • 11.3.7. Thermo Fisher Scientific Inc.
    • 11.3.7.1. Overview,
    • 11.3.7.2. Products,
    • 11.3.7.3. SWOT,
    • 11.3.7.4. Recent Developments,
    • 11.3.7.5. Strategies,
    • 11.3.7.6. Financials (based on availability)
  • 11.3.8. bioMerieux SA
    • 11.3.8.1. Overview,
    • 11.3.8.2. Products,
    • 11.3.8.3. SWOT,
    • 11.3.8.4. Recent Developments,
    • 11.3.8.5. Strategies,
    • 11.3.8.6. Financials (based on availability)
  • 11.3.9. Other Prominent Players
    • 11.3.9.1. Overview,
    • 11.3.9.2. Products,
    • 11.3.9.3. SWOT,
    • 11.3.9.4. Recent Developments,
    • 11.3.9.5. Strategies,
    • 11.3.9.6. Financials (based on availability)

12. Strategic Recommendations